Literature DB >> 22875602

Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab.

Masaki Shimizu1, Kazuyuki Ueno, Akihiro Yachie.   

Abstract

We report the case of a patient with systemic juvenile idiopathic arthritis (s-JIA) receiving tocilizumab (TCZ) who experienced relapses of s-JIA after receiving influenza vaccination. Systemic symptoms of s-JIA might be masked during TCZ therapy. Careful observation with the monitoring of serum interleukin (IL)-18 and IL-6 levels may be useful.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22875602      PMCID： PMC3485886          DOI： 10.1128/CVI.00309-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  6 in total

1.  Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.

Authors:  Nadia E Aikawa; Lucia M A Campos; Clovis A Silva; Jozelio F Carvalho; Carla G S Saad; Guilherme Trudes; Alberto Duarte; Joao L Miraglia; Maria do Carmo S Timenetsky; Vilma S T Viana; Ivan L A França; Eloisa Bonfa; Rosa M R Pereira
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

Review 2.  Should children under treatment for juvenile idiopathic arthritis receive flu vaccination?

Authors:  Liza J McCann
Journal:  Arch Dis Child       Date:  2007-04       Impact factor: 3.791

3.  Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.

Authors:  Laura Dell'Era; Fabrizia Corona; Cristina Daleno; Alessia Scala; Nicola Principi; Susanna Esposito
Journal:  Vaccine       Date:  2011-12-03       Impact factor: 3.641

4.  Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents.

Authors:  Chikara Ogimi; Risa Tanaka; Akihiko Saitoh; Tsutomu Oh-Ishi
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

5.  Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.

Authors:  Toshihiko Shinoki; Ryoki Hara; Utako Kaneko; Takako Miyamae; Tomoyuki Imagawa; Masaaki Mori; Shumpei Yokota
Journal:  Mod Rheumatol       Date:  2012-02-11       Impact factor: 3.023

6.  Influenza immunization in children with chronic arthritis: a prospective study.

Authors:  P N Malleson; J L Tekano; D W Scheifele; J M Weber
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666
  6 in total
  5 in total

Review 1.  Vaccinations in juvenile chronic inflammatory diseases: an update.

Authors:  Clovis A Silva; Nadia E Aikawa; Eloisa Bonfa
Journal:  Nat Rev Rheumatol       Date:  2013-07-02       Impact factor: 20.543

2.  Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations.

Authors:  Marc H Jansen; Christien Rondaan; Geertje Legger; Kirsten Minden; Yosef Uziel; Nataša Toplak; Despoina Maritsi; Mirjam van den Berg; Guy Berbers; Patricia Bruijning; Yona Egert; Christophe Normand; Marc Bijl; Helen Foster; Isabelle Kone-Paut; Carine Wouters; Angelo Ravelli; Ori Elkayam; Nicolaas M Wulffraat; Marloes W Heijstek
Journal:  Front Pediatr       Date:  2022-07-06       Impact factor: 3.569

Review 3.  Vaccinations in paediatric rheumatology: an update on current developments.

Authors:  Noortje Groot; Marloes W Heijstek; Nico M Wulffraat
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

Review 4.  Two flares of Still's disease after two doses of the ChAdOx1 vaccine.

Authors:  Rashmi Roongta; Sumantro Mondal; Subhankar Haldar; Mavidi Sunil Kumar; Alakendu Ghosh
Journal:  Clin Rheumatol       Date:  2022-03-06       Impact factor: 3.650

Review 5.  A flare of Still's disease following COVID-19 vaccination in a 34-year-old patient.

Authors:  Young Hun Jeon; Doo-Ho Lim; Seung Won Choi; Su Jin Choi
Journal:  Rheumatol Int       Date:  2021-11-19       Impact factor: 3.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.